0001415889-24-016939.txt : 20240614 0001415889-24-016939.hdr.sgml : 20240614 20240614163101 ACCESSION NUMBER: 0001415889-24-016939 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240612 FILED AS OF DATE: 20240614 DATE AS OF CHANGE: 20240614 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Heery Christopher CENTRAL INDEX KEY: 0001789632 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41259 FILM NUMBER: 241045357 MAIL ADDRESS: STREET 1: C/O PRECISION BIOSCIENCES, INC. STREET 2: 302 E. PETTIGREW STREET, SUITE A-100 CITY: DURHAM STATE: NC ZIP: 27701 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Arcellx, Inc. CENTRAL INDEX KEY: 0001786205 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 472855917 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 800 BRIDGE PARKWAY CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 240-327-0603 MAIL ADDRESS: STREET 1: 800 BRIDGE PARKWAY CITY: REDWOOD CITY STATE: CA ZIP: 94065 4 1 form4-06142024_080657.xml X0508 4 2024-06-12 0001786205 Arcellx, Inc. ACLX 0001789632 Heery Christopher C/O ARCELLX, INC. 800 BRIDGE PARKWAY REDWOOD CITY CA 94065 false true false false CHIEF MEDICAL OFFICER 1 Common Stock 2024-06-12 4 M 0 7964 6.28 A 17242 D Common Stock 2024-06-12 4 M 0 12036 15 A 29278 D Common Stock 2024-06-12 4 S 0 19918 55.1297 D 9360 D Common Stock 2024-06-12 4 S 0 82 56.0334 D 9278 D Stock Option (right to buy) 6.28 2024-06-12 4 M 0 7964 0 D 2031-06-09 Common Stock 7964 87209 D Stock Option (right to buy) 15 2024-06-12 4 M 0 12036 0 D 2032-02-03 Common Stock 12036 203169 D Includes 340 shares acquired under the Issuer's 2022 Employee Stock Purchase Plan on May 14, 2024. The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on December 22, 2023. Represents the weighted average share price of an aggregate total of 19,918 shares sold in the price range of $55.00 to $55.96 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents the weighted average share price of an aggregate total of 82 shares sold in the price range of $56.02 to $56.04 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 26, 2021. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following the Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Equity Grant Date" shall mean February 3, 2022. /s/ Michelle Gilson, as Attorney-in-Fact 2024-06-14